Valiant Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2025
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Laboratories held its 4th AGM on September 25, 2025, attended by 45 members via video conferencing. Managing Director Santosh Vora acknowledged tough market conditions in FY 2024-25, citing overcapacity and pricing pressure in the paracetamol API segment that hurt revenue and EBITDA. He outlined the company's response, including capacity expansion at the Tarapur facility, supply chain strengthening, and progress on a greenfield project through wholly owned subsidiary Valiant Advanced Sciences Pvt. Ltd. The company also highlighted the development and customer approval of over a dozen specialty chemicals through a new pilot plant, marking diversification beyond paracetamol. Twelve resolutions were transacted, including adoption of FY25 financial statements, reappointment of the Managing Director, appointment of secretarial auditors, several material related party transactions with group companies (Valiant Organics, Aarti Pharmalabs, Alchemie Speciality Chemicals), and revisions to remuneration of executive and non-executive directors.
This is a routine procedural disclosure, but it carries mild negative signals given management's candid admission of revenue and EBITDA pressure in FY25 from paracetamol pricing. The diversification push into specialty chemicals and expansion plans are positives for long-term growth. Shareholders should watch the e-voting results on the director remuneration and related party transaction resolutions, as these are key governance items.